Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2004 | 12-2003 | 12-2002 | 12-2001 | 12-2000 | |
| Sales | 21,426,000 | 18,849,000 | 17,841,000 | 23,570,531 | 18,115,964 |
| Cost of Goods | 5,150,000 | 4,469,000 | 4,520,000 | N/A | N/A |
| Gross Profit | 16,276,000 | 14,380,000 | 13,321,000 | N/A | N/A |
| Operating Expenses | 15,961,000 | 10,269,000 | 9,315,000 | 17,576,793 | 13,642,610 |
| Operating Income | 315,000 | 4,111,000 | 4,006,000 | 5,993,738 | 4,473,354 |
| Interest Expense | N/A | N/A | N/A | 134,807 | 131,437 |
| Other Income | 4,551,000 | 68,000 | 357,000 | -26,961 | -491,397 |
| Pre-tax Income | 4,866,000 | 4,179,000 | 4,363,000 | 5,831,969 | 3,850,520 |
| Income Tax | 1,321,000 | 1,143,000 | 1,177,000 | 1,659,166 | 1,299,438 |
| Net Income Continuous | 3,527,000 | 3,036,000 | 3,186,000 | 4,172,803 | 2,551,081 |
| Net Income Extraordinary | 286,000 | N/A | -350,000 | N/A | N/A |
| Minority Interests | -18,000 | -23,000 | -24,000 | -16,592 | -10,455 |
| Net Income | $3,813,000 | $3,036,000 | $2,836,000 | $4,156,211 | $2,540,626 |
| EPS Basic Total Ops | 2.28 | 1.78 | 1.64 | 2.43 | 1.43 |
| EPS Basic Continuous Ops | 2.11 | 1.78 | 1.84 | 2.43 | 1.43 |
| EPS Basic Discontinuous Ops | 0.17 | 0.00 | -0.20 | 0.00 | 0.00 |
| EPS Diluted Total Ops | 2.28 | 1.78 | 1.64 | 2.43 | 1.43 |
| EPS Diluted Continuous Ops | 2.11 | 1.78 | 1.64 | 2.43 | 1.43 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | -0.20 | 0.00 | 0.00 |
| EBITDA(a) | $1,583,000 | $5,401,000 | $4,966,000 | $7,148,933 | $4,910,981 |